Clinical Trials Browser

Maximum Tolerated Dose × Plasma cell × Clear all

NCT05976555 2025-06-11

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma

NCT02477215 2020-10-22

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

38 enrolled 18 charts

Multiple Myeloma